P2Y12 — Drug Target

All drugs that target P2Y12 — marketed and clinical-stage. Includes 3 drug classes acting on this target.

Drug classes

P2Y12 receptor antagonist · P2Y12 receptor inhibitor · ADP receptor inhibitor

Marketed (5)

• P2Y12 antagonist monotherapy · Samsung Medical Center · P2Y12 receptor antagonist · Cardiovascular
  P2Y12 antagonists block the P2Y12 adenosine diphosphate receptor on platelet surfaces, preventing platelet aggregation and thrombus formation.
• low-dose ticagrelor · First Affiliated Hospital of Harbin Medical University · P2Y12 receptor antagonist · Cardiovascular
  Low-dose ticagrelor inhibits the P2Y12 adenosine diphosphate receptor on platelets to reduce platelet aggregation and thrombotic events.
• standard-dose ticagrelor · First Affiliated Hospital of Harbin Medical University · P2Y12 receptor antagonist · Cardiovascular
  Ticagrelor is a P2Y12 receptor antagonist that irreversibly blocks platelet activation and aggregation, reducing thrombotic events.
• Ticagrelor first · Ping-Yen Liu · P2Y12 receptor antagonist · Cardiovascular
  Ticagrelor is a direct-acting P2Y12 receptor antagonist that inhibits platelet aggregation by blocking adenosine diphosphate (ADP) signaling.
• half-dose ticagrelor · First Affiliated Hospital of Harbin Medical University · P2Y12 receptor antagonist · Cardiovascular
  Half-dose ticagrelor inhibits the P2Y12 adenosine diphosphate receptor on platelets to reduce platelet aggregation and thrombotic events.

Phase 3 pipeline (1)

• The ticagrelor · Sichuan Provincial People's Hospital · P2Y12 receptor inhibitor · Cardiovascular
  Ticagrelor is a platelet aggregation inhibitor that works by blocking the P2Y12 receptor.

Phase 2 pipeline (1)

• ADP receptor inhibitors · Eli Lilly and Company · ADP receptor inhibitor · Cardiovascular
  ADP receptor inhibitors block the action of ADP on its receptor, preventing platelet activation and aggregation.